Evidence map›Paper›PMID 29216908›Full record

ArticleActa neuropathologica communications2017

Clinical and neuropathological features of ALS/FTD with TIA1 mutations.

Veronica Hirsch-Reinshagen, Cyril Pottier, Alexandra M Nicholson, Matt Baker, Ging-Yuek R Hsiung, Charles Krieger, Pheth Sengdy, Kevin B Boylan, Dennis W Dickson, Marsel Mesulam and 10 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Veronica Hirsch-ReinshagenDepartment of Pathology and Laboratory Medicine, University of British Colombia, British Columbia, Canada.
Cyril PottierDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Alexandra M NicholsonDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Matt BakerDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Ging-Yuek R HsiungDivision of Neurology, University of British Columbia, Vancouver, BC, Canada.
Charles KriegerDepartment of Biomedical Physiology & Kinesiology, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
Pheth SengdyDivision of Neurology, University of British Columbia, Vancouver, BC, Canada.
Kevin B BoylanDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Marsel MesulamDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sandra WeintraubDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Eileen BigioDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Lorne ZinmanDivision of Neurology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Julia KeithDepartment of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Ekaterina RogaevaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Sasha A ZivkovicDepartment of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
David LacomisDepartment of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Paul TaylorDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, USA.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Ian R A MackenzieDepartment of Pathology and Laboratory Medicine, University of British Colombia, British Columbia, Canada. ian.mackenzie@vch.ca.
Mayo Clinic in Florida · USNorthwestern University · USUniversity of British Columbia · CAJacksonville College · USSunnybrook Health Science Centre · CAUniversity of Pittsburgh · USSimon Fraser University · CASt. Jude Children's Research Hospital · USUniversity of Toronto · CAVancouver Coastal Health · CA

Funding

Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIGIO, EILEEN H. · 1996 to 2020
$28.9M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Genetic Discovery and Pathobiology of Frontotemporal Lobar Degeneration and Related TDP-43 ProteinopathiesR35NS097261 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2017 to 2019
$2.9M
ALS Canada-Brain Canada Hudson GrantCanadian Consortium on Neurodegeneration in Aging 137794Canadian Institutes of Health Research 74580National Institute of Neurological Disorders and Stroke P01 NS084974National Institute of Neurological Disorders and Stroke (US) R35 NS097261National Institute on Aging P30 AG13854NIA NIH HHS P30 AG013854NINDS NIH HHS P01 NS084974NINDS NIH HHS R35 NS097261
6 · The paper itself

Abstract

Mutations in the stress granule protein T-cell restricted intracellular antigen 1 (TIA1) were recently shown to cause amyotrophic lateral sclerosis (ALS) with or without frontotemporal dementia (FTD). Here, we provide detailed clinical and neuropathological descriptions of nine cases with TIA1 mutations, together with comparisons to sporadic ALS (sALS) and ALS due to repeat expansions in C9orf72 (C9orf72+). All nine patients with confirmed mutations in TIA1 were female. The clinical phenotype was heterogeneous with a range in the age at onset from late twenties to the eighth decade (mean = 60 years) and disease duration from one to 6 years (mean = 3 years). Initial presentation was either focal weakness or language impairment. All affected individuals received a final diagnosis of ALS with or without FTD. No psychosis or parkinsonism was described. Neuropathological examination on five patients found typical features of ALS and frontotemporal lobar degeneration (FTLD-TDP, type B) with anatomically widespread TDP-43 proteinopathy. In contrast to C9orf72+ cases, caudate atrophy and hippocampal sclerosis were not prominent. Detailed evaluation of the pyramidal motor system found a similar degree of neurodegeneration and TDP-43 pathology as in sALS and C9orf72+ cases; however, cases with TIA1 mutations had increased numbers of lower motor neurons containing round eosinophilic and Lewy body-like inclusions on HE stain and round compact cytoplasmic inclusions with TDP-43 immunohistochemistry. Immunohistochemistry and immunofluorescence failed to demonstrate any labeling of inclusions with antibodies against TIA1. In summary, our TIA1 mutation carriers developed ALS with or without FTD, with a wide range in age at onset, but without other neurological or psychiatric features. The neuropathology was characterized by widespread TDP-43 pathology, but a more restricted pattern of neurodegeneration than C9orf72+ cases. Increased numbers of round eosinophilic and Lewy-body like inclusions in lower motor neurons may be a distinctive feature of ALS caused by TIA1 mutations.

Indexed as

AdultAgedAmyotrophic Lateral SclerosisAutopsyC9orf72 ProteinDNA-Binding ProteinsFamily HealthFemaleFrontotemporal DementiaHumansMaleMiddle AgedMutationNeuropathologyT-Cell Intracellular Antigen-1C9orf72 ProteinDNA-Binding ProteinsTARDBP protein, humanT-Cell Intracellular Antigen-1TIA1 protein, humanAmyotrophic lateral sclerosisFrontotemporal dementiaFrontotemporal lobar degenerationT-cell restricted intracellular antigen-1TDP-43

Identifiers

PMID29216908
PMCPMC5719900
OpenAlexW2775465654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.